AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35924312 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy (iCBT)
Number of subjects: 21
Study 35924312 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 21
Study 33122486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic period (TURKMI-2)
Number of subjects: 1113
Study 34463952 — intervention group
Group type: EXPERIMENTAL
Intervention: ColourSpot app
Number of subjects: 772
Study 34463952 — intervention group
Group type: COMPARATOR
Intervention: Ishihara Unlettered test
Number of subjects: 772
Study 34463952 — intervention group
Group type: COMPARATOR
Intervention: Neitz Test
Number of subjects: 772
Study 32108442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet breakfast (30% by weight added sugar; average 32 g of sugar)
Number of subjects: 29
Study 32108442 — intervention group
Group type: COMPARATOR
Intervention: Plain breakfast (no added sugar; average 8 g of sugar)
Number of subjects: 29
Study 32108442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet breakfast
Number of subjects: 29
Study 35451977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity digital promotion in privileged urban localities
Number of subjects: 27
Study 35451977 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional high-intensity promotion in less privileged urban localities
Number of subjects: 27
Study 35451977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity promotion in rural localities
Number of subjects: 27
Study 34698782 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections (n=48)
Number of subjects: 100
Study 34698782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injections (n=52)
Number of subjects: 100
Study 34698782 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PRP vs Placebo
Number of subjects: 100
Study 32006293 — intervention group
Group type: EXPERIMENTAL
Intervention: MISSION-CJ intervention
Number of subjects: 26
Study 32006293 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 34225027 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reinforcement for every correct response on a theory of mind (ToM) task
Number of subjects: 70
Study 34225027 — intervention group
Group type: COMPARATOR
Intervention: Non-reward condition with no feedback
Number of subjects: 70
Study 35559516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Number of subjects: 0
Study 32491941 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Learning (CAL)
Number of subjects: 60
Study 32491941 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation Clinic (SIM)
Number of subjects: 60
Study 32491941 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60
Study 34735285 — intervention group
Group type: EXPERIMENTAL
Intervention: Research staff obtained ESAS
Number of subjects: 3533
Study 34735285 — intervention group
Group type: COMPARATOR
Intervention: Clinically collected ESAS by nurses
Number of subjects: 3533
Study 34735285 — intervention group
Group type: COMPARATOR
Intervention: Proxy-reported ESAS
Number of subjects: 3533
Study 34735285 — intervention group
Group type: COMPARATOR
Intervention: Clinically collected ESAS by proxies
Number of subjects: 3533
Study 34735285 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up ESAS measures
Number of subjects: 3533
Study 36505223 — intervention group
Group type: EXPERIMENTAL
Intervention: USG-guided femoral nerve block (FNB) and lateral femoral cutaneous nerve block (LFCNB) using 0.75% ropivacaine before SAB
Number of subjects: 60
Study 36505223 — intervention group
Group type: COMPARATOR
Intervention: SAB only
Number of subjects: 60
Study 36505223 — intervention group
Group type: EXPERIMENTAL
Intervention: USG-guided FNB and LFCNB
Number of subjects: 60
Study 35792831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid with chondroitin sulphate (HA+CS)
Number of subjects: 10
Study 32827307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nimodipine treatment (parenteral nimodipine from the day before surgery until the seventh postoperative day)
Number of subjects: 40
Study 32827307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nimodipine treatment
Number of subjects: 40
Study 32827307 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 40
Study 35063028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabronchial administration of autologous adipose-derived mesenchymal stem cells (AD-MSC)
Number of subjects: 20
Study 35063028 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone
Number of subjects: 20
Study 34789149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Toolbox (used for 3 months)
Number of subjects: 32
Study 34789149 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (toolbox after follow-up)
Number of subjects: 32
Study 32165444 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA diet
Number of subjects: 16
Study 32165444 — intervention group
Group type: COMPARATOR
Intervention: SUGAR diet
Number of subjects: 16
Study 616600062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal cell phone conversation
Number of subjects: 99
Study 616600062 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting conversation
Number of subjects: 99
Study 616600062 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 35485693 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified premedication protocol without ranitidine
Number of subjects: 441
Study 35485693 — intervention group
Group type: COMPARATOR
Intervention: Standard premedication protocol with ranitidine
Number of subjects: 441
Study 32036375 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + HEB
Number of subjects: 207
Study 32036375 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 207
Study 33583208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-conducted telephone guidance for bowel preparation before colonoscopy
Number of subjects: 109
Study 33583208 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine recommendations without telephone guidance)
Number of subjects: 109
Study 32469375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Mapping (MM) group, instructed on how to construct mind maps and created weekly mind maps for 9 weeks.
Number of subjects: 74
Study 32469375 — intervention group
Group type: COMPARATOR
Intervention: Standard Note-Taking Group (SNTG), followed their method of study without mind maps for 9 weeks.
Number of subjects: 74
Study 33495909 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic Focus (HF)
Number of subjects: 60
Study 33495909 — intervention group
Group type: EXPERIMENTAL
Intervention: External Focus (EF)
Number of subjects: 60
Study 33495909 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 33495909 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Focus (IF)
Number of subjects: 60
Study 32852619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enriched oil-based gel dressing (G1)
Number of subjects: 114
Study 32852619 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid cream (G2)
Number of subjects: 114
Study 35587950 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coping (above-average)
Number of subjects: 194
Study 35587950 — intervention group
Group type: EXPERIMENTAL
Intervention: Community connectedness at baseline
Number of subjects: 194
Study 35587950 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-person change in active coping
Number of subjects: 194
Study 35587950 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-person change in community connectedness
Number of subjects: 194
Study 33618811 — intervention group
Group type: EXPERIMENTAL
Intervention: Video discharge instructions (verbal, written, and video discharge information)
Number of subjects: 771
Study 33618811 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal and written discharge information only)
Number of subjects: 771
Study 32326983 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training program led by childcare educators (n=185 children)
Number of subjects: 361
Study 32326983 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (n=176 children)
Number of subjects: 361
Study 36228127 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted diagnosis
Number of subjects: 104
Study 36228127 — intervention group
Group type: COMPARATOR
Intervention: Independent diagnosis
Number of subjects: 104
Study 33544534 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training (RT)
Number of subjects: 65
Study 33544534 — intervention group
Group type: EXPERIMENTAL
Intervention: Instability training (IT)
Number of subjects: 65
Study 33544534 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (PLY)
Number of subjects: 65
Study 33838918 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital dentures (2 visits)
Number of subjects: 16
Study 33838918 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures (5 visits)
Number of subjects: 16
Study 33838918 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital dentures
Number of subjects: 16
Study 33838918 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 16
Study 34476247 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention (physical activity promotion through personalised, progressive step-count goals, feedback, online COPD-related education and social support via an online community)
Number of subjects: 153
Study 34476247 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study 35545881 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 40
Study 35545881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32155289 — intervention group
Group type: EXPERIMENTAL
Intervention: PREOP risk score higher than 8
Number of subjects: 229
Study 32155289 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 229
Study 32169297 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 RCTs
Number of subjects: 303
Study 34369853 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine massage
Number of subjects: 176
Study 34369853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study 32300910 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional communication training (FCT) via telehealth
Number of subjects: 38
Study 32300910 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 38
Study 35840308 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the collar (intervention)
Number of subjects: 887
Study 35840308 — intervention group
Group type: COMPARATOR
Intervention: Hard collar (standard care)
Number of subjects: 887
Study 33840404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), n=33
Number of subjects: 68
Study 33840404 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX), n=35
Number of subjects: 68
Study 35978286 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 3345
Study 35978286 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 3345
Study 35978286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3345
Study 35978286 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg and 140 mg
Number of subjects: 3345
Study 33880769 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded principal stratification framework allowing for partial adherence
Number of subjects: 0
Study 33880769 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo posterior sampling method
Number of subjects: 0
Study 33323545 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte telomere length (LTL) as instrument variables using 5 independent SNPs
Number of subjects: 0
Study 33323545 — intervention group
Group type: EXPERIMENTAL
Intervention: MR‐Egger intercept test
Number of subjects: 0
Study 33323545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochran's Q test and I2 statistics
Number of subjects: 0
Study 33323545 — intervention group
Group type: EXPERIMENTAL
Intervention: Leave‐one‐out sensitivity analysis
Number of subjects: 0
Study 33454539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-computer with survivor stories (3 times in 12 months)
Number of subjects: 228
Study 33454539 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 228
Study 32384175 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 0
Study 32384175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35150025 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment of physical function limitations using the Activities Scale for Kids©
Number of subjects: 41
Study 35150025 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment of exercise-related ADLs simulated with the Functional ADL Screen
Number of subjects: 41
Study 35150025 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment of motor performance using the Motor Performance in Paediatric Oncology test
Number of subjects: 41
Study 35150025 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment of physical activity level measured using an accelerometer
Number of subjects: 41
Study 35150025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative steroid dose
Number of subjects: 41
Study 33620545 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (140 mL, 13 mmol NO3‐)
Number of subjects: 10
Study 33620545 — intervention group
Group type: COMPARATOR
Intervention: NO3‐‐free placebo (PLA)
Number of subjects: 10
Study 33620545 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation
Number of subjects: 10
Study 32892178 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 305
Study 32892178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 35665223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangeretin (200 mg/day)
Number of subjects: 24
Study 35665223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33538566 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel topical cosmetic cream (NCC), applied twice daily.
Number of subjects: 0
Study 36463547 — intervention group
Group type: EXPERIMENTAL
Intervention: pertuzumab, trastuzumab, and docetaxel
Number of subjects: 243
Study 36463547 — intervention group
Group type: COMPARATOR
Intervention: placebo, trastuzumab, and docetaxel
Number of subjects: 243
Study 34446544 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (150 mg/kg)
Number of subjects: 60
Study 34446544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34446544 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 60
Study 32119035 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD10 (10 mg/kg/d)
Number of subjects: 199
Study 32119035 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD20 (20 mg/kg/d)
Number of subjects: 199
Study 32119035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 35672606 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3/6 dietary supplement (two capsules containing 279 mg EPA, 87 mg DHA, 30 mg GLA each)
Number of subjects: 160
Study 35672606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 35672606 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3/6 dietary supplement
Number of subjects: 160
Study 32162813 — intervention group
Group type: EXPERIMENTAL
Intervention: IV NEPA (fosnetupitant/palonosetron)
Number of subjects: 402
Study 32162813 — intervention group
Group type: COMPARATOR
Intervention: Oral NEPA
Number of subjects: 402
Study 35878448 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention delivered by Anganwadi workers in 25 intervention clusters, with caregivers attending an average of five out of nine scheduled sessions.
Number of subjects: 530
Study 35878448 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 530
Study 33103938 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention (PCI)
Number of subjects: 479
Study 33103938 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 479
Study 35325589 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies across four randomized experiments
Number of subjects: 0
Study 35325589 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies across four randomized experiments
Number of subjects: 0
Study 35325589 — intervention group
Group type: EXPERIMENTAL
Intervention: Student feedback on participation improvement strategies
Number of subjects: 0
Study 35325589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory intervention completion at one university
Number of subjects: 0
Study 32176674 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersive VR training using a RAPAEL smart glove for 30 minutes per session, 3 days a week for 8 weeks
Number of subjects: 36
Study 32176674 — intervention group
Group type: COMPARATOR
Intervention: Recreational activities for 30 minutes per session, 3 days a week for 8 weeks (control group)
Number of subjects: 36
Study 33257933 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sustained ventricular tachycardia (NSVT)
Number of subjects: 850
Study 33257933 — intervention group
Group type: EXPERIMENTAL
Intervention: High burden PVC
Number of subjects: 850
Study 33257933 — intervention group
Group type: COMPARATOR
Intervention: Neither NSVT nor high burden of PVC
Number of subjects: 850
Study 33061328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting risk of injurious falls
Number of subjects: 345
Study 33061328 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors identified
Number of subjects: 345
Study 33061328 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curves
Number of subjects: 345
Study 35941301 — intervention group
Group type: EXPERIMENTAL
Intervention: Single step dilatation (group B)
Number of subjects: 70
Study 35941301 — intervention group
Group type: COMPARATOR
Intervention: Serial metal track dilatation (group A)
Number of subjects: 70
Study 34352149 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of Tenofovir Alafenamide (TAF)
Number of subjects: 68
Study 34352149 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of Tenofovir Alafenamide (TAF)
Number of subjects: 68
Study 32559257 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher admission systolic blood pressure (SBP)
Number of subjects: 21364
Study 32559257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower admission systolic blood pressure (SBP)
Number of subjects: 21364
Study 35230615 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Day Good Behavior Game (WD)
Number of subjects: 961
Study 35230615 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 961
Study 33625515 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + VR
Number of subjects: 61
Study 33625515 — intervention group
Group type: COMPARATOR
Intervention: Usual CR care
Number of subjects: 61
Study 35701331 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote-based monitoring and education program (three educational sessions by telephone)
Number of subjects: 134
Study 35797913 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS treatment
Number of subjects: 42
Study 35797913 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS treatment
Number of subjects: 42
Study 33377972 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib, 480 mg orally twice daily for 4 days on and 3 days off weekly in 28-day cycles; 400 mg if continuing hormone therapy for metastatic breast cancer.
Number of subjects: 35
Study 33377972 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib
Number of subjects: 35
Study 32065880 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI; ≥92.5%)
Number of subjects: 120
Study 32065880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34588374 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal jelly 690 mg daily for 4 weeks
Number of subjects: 100
Study 34588374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32707226 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut (food challenge)
Number of subjects: 57
Study 32707226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluids (administered post-reaction)
Number of subjects: 57
Study 32707226 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat peanut challenge
Number of subjects: 57
Study 35986418 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable buprenorphine (BUP-XR)
Number of subjects: 304
Study 35986418 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable buprenorphine (BUP-XR) with adjunctive psychosocial interventions (PSI)
Number of subjects: 304
Study 35986418 — intervention group
Group type: COMPARATOR
Intervention: Sublingual tablet buprenorphine (BUP-SL)
Number of subjects: 304
Study 35986418 — intervention group
Group type: COMPARATOR
Intervention: Oral liquid methadone (MET)
Number of subjects: 304
Study 35986418 — intervention group
Group type: COMPARATOR
Intervention: Sublingual tablet buprenorphine (BUP-SL) with PSI
Number of subjects: 304
Study 35986418 — intervention group
Group type: COMPARATOR
Intervention: Oral liquid methadone (MET) with PSI
Number of subjects: 304
Study 32253962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive computer-based phonics (GraphoGame, GG)
Number of subjects: 17
Study 32253962 — intervention group
Group type: COMPARATOR
Intervention: Regular schooling (RS)
Number of subjects: 17
Study 32253962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive computer-based phonics (GraphoGame, GG) after one period
Number of subjects: 17